Subscribe - Individual

Subscribe - Biotech Premium (Corporate)


April 6th, 2023

Imugene - Nine Clinical Programs to Advance in 2023

Imugene (IMU: $0.15) has in-licensed three core technologies. The first and the one on which the company was founded was HER-Vaxx (2013). This technology stimulates the body to develop antibodies against HER2, which is present on breast and gastric tumours in specific patients (who are HER2 positive).

April 6th, 2023

Imricor Focuses on Dedicated iCMR Labs

Imricor (IMR: $0.29) is seeking to introduce a new standard-of-care in cardiac ablation procedures. That involves using MRI rather than x-ray to guide the procedures which arguably provides better real-time, functional information on how best to correct irregular heart function.

April 6th, 2023

Chimeric Therapeutics - Viral Vector Manufacturing Achieved

Chimeric Therapeutics (CHM: $0.076) is commercialising cell therapy technologies sourced from three US research institutions to treat a range of poorly addressed cancers. Patients with these diseases had a five-year survival expectation of just 5% - 27%.

April 6th, 2023

Anteris Technologies - Early Feasibility Study to Start Ahead of 1,000 Patient Pivotal Trial

Anteris Technologies (AVR: $21.50) is commercialising the DurAVR aortic heart valve which is implanted by catheter rather than open chest surgery. It is seeking to launch its product in coming years in a market estimated to be worth US$10 billion in 2028, based on only a 15%-20% penetration base of the current patients, according to CEO Wayne Paterson.

April 6th, 2023

Aroa Biosurgery - Manufacturing Capacity to Reach NZ$150 Million

Aroa Biosurgery (ARX: $1.08) describes itself as a high growth tissue regeneration company. That high growth has been achieved in FY2023 (its financial year ends 31 March) with annual sales expected to reach the target NZ$60 - NZ$62 million, up at least 54% on the previous year.

March 17th, 2023

From Benchtop to the Clinic - Stunning Success for Neuren Pharmaceuticals

Terms: Trofinetide brand name is DAYBUE in North America.

A book was written in 1994 about US biotech company Vertex Pharmaceuticals called The Billion Dollar Molecule. Last week Neuren Pharmaceuticals (NEU: $13.23) may have been successful in achieving that quest - with approval in the US, through its partner Acadia Pharmaceuticals, of the drug which has been renamed DAYBUE (formerly trofinetide) for the treatment of Retts syndrome.

February 24th, 2023

Opthea - Full Recruitment to Trigger Results Countdown

Opthea (OPT: $0.85) is currently conducting two Phase III studies with its ophthalmic drug candidate, OPT-302, for the treatment of wet AMD. Those trials are seeking to recruit just under 2,000 people. With completion of recruitment approaching, that major milestone will trigger a countdown to the pending results a little over 12 months later, which should see considerable interest build in the stock.

February 24th, 2023

Neuren Pharmaceuticals - FDA Decision on Trofinetide Approaching

Arguably the most significant event for the Australian biotech sector is approaching with a decision expected from the FDA on the approval of trofinetide, developed by Neuren Pharmaceuticals (NEU: $7.16), on 12 March.

February 24th, 2023

EBR Systems - Pivotal Results Due Q2

EBR Systems (EBR: $0.60) is a relatively new biotech on the ASX, having listed in November 2021 at $1.08 per share, raising $110 million. It is developing the world's first and only wireless electronic heart pacing system for the left ventricular, called WiSE. It is being trialled with commercially available right ventricle pacers (both with leads and wireless) to offer a novel cardiac resynchronisation therapy (CRT).